Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results [Yahoo! Finance]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The company is preparing to enroll patients in Phase 3 SYNCHRONY studies by the end of 2023. Akero's cash reserves are substantial, with the company having enough funds to operate into 2026. Net loss for the quarter was $39.7 million, with research and development expenses being a significant contributor. Warning! GuruFocus has detected 2 Warning Sign with AKRO. On November 13, 2023, Akero Therapeutics Inc ( NASDAQ:AKRO ) released its 8-K filing , detailing the company's financial results for the third quarter ending September 30, 2023. The clinical-stage company, which focuses on developing treatments for serious metabolic diseases, is moving forward with its lead product candidate, Efruxifermin (EFX), for the treatment of non-alcoholic steatohepatitis (NASH). Financial Highlights Akero Therapeutics reported a net loss of $39.7 million for the third quarter of 2023, compared to a net loss of $35.5 million for the same period in 2022. The increase in net loss was primaril
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Akero Therapeutics (NASDAQ:AKRO) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKROBusiness Wire
- Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)PR Newswire
AKRO
Earnings
- 8/8/25 - Beat
AKRO
Sec Filings
- 12/9/25 - Form 25-NSE
- 12/9/25 - Form 4
- 12/9/25 - Form 4
- AKRO's page on the SEC website